Skip to main content
Top
Published in: Journal of Bone and Mineral Metabolism 2/2019

01-03-2019 | Letter to the Editor

Hepatosplenomegaly, pneumopathy, bone changes and fronto-temporal dementia: Niemann–Pick type B and SQSTM1-associated Paget’s disease in the same individual

Authors: Camelia Voinea, Elena Gonzalez Rodriguez, Catherine Beigelman-Aubry, Victor Leroy, Bérengère Aubry-Rozier, Belinda Campos-Xavier, Diana Ballhausen, Romain Lazor, Frédéric Barbey, Luisa Bonafé, Andrea Superti-Furga, Christel Tran

Published in: Journal of Bone and Mineral Metabolism | Issue 2/2019

Login to get access

Abstract

Data from exome sequencing show that a proportion of individuals in whom a genetic disorder is suspected turn out to have not one, but two to four distinct ones. This may require an evolution in our diagnostic attitude towards individuals with complex disorders. We report a patient with splenomegaly, pneumopathy, bone changes and fronto-temporal dementia (FTD). “Sea-blue histiocytes” in his bone marrow pointed to a lysosomal storage disease. Homozygosity for a pathogenic mutation in the SMPD1 gene confirmed Niemann–Pick disease type B (NPD-B). Mild cognitive impairment and abnormal brain FDG PET were consistent with FTD. We initially tried to fit the skeletal and neurologic phenotype into the NPD-B diagnosis. However, additional studies revealed a pathogenic mutation in the SQSTM1 gene. Thus, our patient had two distinct diseases; NPD-B, and Paget’s disease of bone with FTD. The subsequent finding of a mutation in SQSTM1 gene ended our struggle to explain the combination of findings by a singular “unifying” diagnosis and allowed us to make specific therapeutic decisions. SQSTM1 mutations have been reported in association with FTD, possibly because of defective autophagy. Bisphosphonates may be beneficial for PDB, but since they are known to inhibit acid sphingomyelinase activity, we refrained from using them in this patient. While the principle of looking for unifying diagnosis remains valid, physicians should consider the possibility of co-existing multiple diagnoses when clinical features are difficult to explain by a single one. Accurate diagnostic work-up can guide genetic counseling but also lead to better medical management.
Literature
1.
2.
go back to reference Victor S, Coulter JB, Besley GT, Ellis I, Desnick RJ, Schuchman EH, Vellodi A (2003) Niemann–Pick disease: sixteen-year follow-up of allogeneic bone marrow transplantation in a type B variant. J Inherit Metab Dis 26:775–785CrossRefPubMed Victor S, Coulter JB, Besley GT, Ellis I, Desnick RJ, Schuchman EH, Vellodi A (2003) Niemann–Pick disease: sixteen-year follow-up of allogeneic bone marrow transplantation in a type B variant. J Inherit Metab Dis 26:775–785CrossRefPubMed
3.
go back to reference Wasserstein MP, Jones SA, Soran H, Diaz GA, Lippa N, Thurberg BL, Culm-Merdek K, Shamiyeh E, Inguilizian H, Cox GF, Puga AC (2015) Successful within-patient dose escalation of olipudase alfa in acid sphingomyelinase deficiency. Mol Genet Metab 116:88–97CrossRefPubMedPubMedCentral Wasserstein MP, Jones SA, Soran H, Diaz GA, Lippa N, Thurberg BL, Culm-Merdek K, Shamiyeh E, Inguilizian H, Cox GF, Puga AC (2015) Successful within-patient dose escalation of olipudase alfa in acid sphingomyelinase deficiency. Mol Genet Metab 116:88–97CrossRefPubMedPubMedCentral
4.
go back to reference Wasserstein M, Godbold J, McGovern MM (2013) Skeletal manifestations in pediatric and adult patients with Niemann Pick disease type B. J Inherit Metab Dis 36:123–127CrossRefPubMed Wasserstein M, Godbold J, McGovern MM (2013) Skeletal manifestations in pediatric and adult patients with Niemann Pick disease type B. J Inherit Metab Dis 36:123–127CrossRefPubMed
5.
go back to reference Daroszewska A, Ralston SH (2005) Genetics of Paget’s disease of bone. Clin Sci (Lond) 109:257–263CrossRef Daroszewska A, Ralston SH (2005) Genetics of Paget’s disease of bone. Clin Sci (Lond) 109:257–263CrossRef
6.
go back to reference Wenstrup RJ, Roca-Espiau M, Weinreb NJ, Bembi B (2002) Skeletal aspects of Gaucher disease: a review. Br J Radiol 75:A2–12CrossRefPubMed Wenstrup RJ, Roca-Espiau M, Weinreb NJ, Bembi B (2002) Skeletal aspects of Gaucher disease: a review. Br J Radiol 75:A2–12CrossRefPubMed
7.
go back to reference van Diggelen OP, Voznyi YV, Keulemans JL, Schoonderwoerd K, Ledvinova J, Mengel E, Zschiesche M, Santer R, Harzer K (2005) A new fluorimetric enzyme assay for the diagnosis of Niemann–Pick A/B, with specificity of natural sphingomyelinase substrate. J Inherit Metab Dis 28:733–741CrossRefPubMed van Diggelen OP, Voznyi YV, Keulemans JL, Schoonderwoerd K, Ledvinova J, Mengel E, Zschiesche M, Santer R, Harzer K (2005) A new fluorimetric enzyme assay for the diagnosis of Niemann–Pick A/B, with specificity of natural sphingomyelinase substrate. J Inherit Metab Dis 28:733–741CrossRefPubMed
8.
go back to reference Levran O, Desnick RJ, Schuchman EH (1991) Niemann–Pick type B disease. Identification of a single codon deletion in the acid sphingomyelinase gene and genotype/phenotype correlations in type A and B patients. J Clin Invest 88:806–810CrossRefPubMedPubMedCentral Levran O, Desnick RJ, Schuchman EH (1991) Niemann–Pick type B disease. Identification of a single codon deletion in the acid sphingomyelinase gene and genotype/phenotype correlations in type A and B patients. J Clin Invest 88:806–810CrossRefPubMedPubMedCentral
9.
go back to reference Posey JE, Harel T, Liu P, Rosenfeld JA, James RA et al (2017) Resolution of disease phenotypes resulting from multilocus genomic variation. N Engl J Med 376:21–31CrossRefPubMed Posey JE, Harel T, Liu P, Rosenfeld JA, James RA et al (2017) Resolution of disease phenotypes resulting from multilocus genomic variation. N Engl J Med 376:21–31CrossRefPubMed
11.
go back to reference Volders P, Van Hove J, Lories RJ, Vandekerckhove P, Matthijs G, De Vos R, Vanier MT, Vincent MF, Westhovens R, Luyten FP (2002) Niemann–Pick disease type B: an unusual clinical presentation with multiple vertebral fractures. Am J Med Genet 109:42–51CrossRefPubMed Volders P, Van Hove J, Lories RJ, Vandekerckhove P, Matthijs G, De Vos R, Vanier MT, Vincent MF, Westhovens R, Luyten FP (2002) Niemann–Pick disease type B: an unusual clinical presentation with multiple vertebral fractures. Am J Med Genet 109:42–51CrossRefPubMed
12.
go back to reference Muntaner L, Galmes A, Chabas A, Herrera M (1997) Imaging features of type-B Niemann–Pick disease. Eur Radiol 7:361–364CrossRefPubMed Muntaner L, Galmes A, Chabas A, Herrera M (1997) Imaging features of type-B Niemann–Pick disease. Eur Radiol 7:361–364CrossRefPubMed
13.
go back to reference McGovern MM, Wasserstein MP, Giugliani R, Bembi B, Vanier MT, Mengel E, Brodie SE, Mendelson D, Skloot G, Desnick RJ, Kuriyama N, Cox GF (2008) A prospective, cross-sectional survey study of the natural history of Niemann–Pick disease type B. Pediatrics 122:e341–e349CrossRefPubMed McGovern MM, Wasserstein MP, Giugliani R, Bembi B, Vanier MT, Mengel E, Brodie SE, Mendelson D, Skloot G, Desnick RJ, Kuriyama N, Cox GF (2008) A prospective, cross-sectional survey study of the natural history of Niemann–Pick disease type B. Pediatrics 122:e341–e349CrossRefPubMed
14.
go back to reference Vallet M, Ralston SH (2016) Biology and treatment of Paget’s disease of bone. J Cell Biochem 117:289–299CrossRefPubMed Vallet M, Ralston SH (2016) Biology and treatment of Paget’s disease of bone. J Cell Biochem 117:289–299CrossRefPubMed
15.
go back to reference Rea SL, Majcher V, Searle MS, Layfield R (2014) SQSTM1 mutations–bridging Paget disease of bone and ALS/FTLD. Exp Cell Res 325:27–37CrossRefPubMed Rea SL, Majcher V, Searle MS, Layfield R (2014) SQSTM1 mutations–bridging Paget disease of bone and ALS/FTLD. Exp Cell Res 325:27–37CrossRefPubMed
16.
go back to reference Rubino E, Rainero I, Chio A, Rogaeva E, Galimberti D, Fenoglio P, Grinberg Y, Isaia G, Calvo A, Gentile S, Bruni AC, St George-Hyslop PH, Scarpini E, Gallone S, Pinessi L, T.S. Group (2012) SQSTM1 mutations in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Neurology 79:1556–1562CrossRefPubMedPubMedCentral Rubino E, Rainero I, Chio A, Rogaeva E, Galimberti D, Fenoglio P, Grinberg Y, Isaia G, Calvo A, Gentile S, Bruni AC, St George-Hyslop PH, Scarpini E, Gallone S, Pinessi L, T.S. Group (2012) SQSTM1 mutations in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Neurology 79:1556–1562CrossRefPubMedPubMedCentral
17.
go back to reference Hocking LJ, Whitehouse C, Helfrich MH (2012) Autophagy: a new player in skeletal maintenance? J Bone Miner Res 27:1439–1447CrossRefPubMed Hocking LJ, Whitehouse C, Helfrich MH (2012) Autophagy: a new player in skeletal maintenance? J Bone Miner Res 27:1439–1447CrossRefPubMed
18.
19.
go back to reference Gabande-Rodriguez E, Boya P, Labrador V, Dotti CG, Ledesma MD (2014) High sphingomyelin levels induce lysosomal damage and autophagy dysfunction in Niemann Pick disease type A. Cell Death Differ 21:864–875CrossRefPubMedPubMedCentral Gabande-Rodriguez E, Boya P, Labrador V, Dotti CG, Ledesma MD (2014) High sphingomyelin levels induce lysosomal damage and autophagy dysfunction in Niemann Pick disease type A. Cell Death Differ 21:864–875CrossRefPubMedPubMedCentral
20.
go back to reference Ishii M, Kikuta J (1831) Sphingosine-1-phosphate signaling controlling osteoclasts and bone homeostasis. Biochim Biophys Acta 2013:223–227 Ishii M, Kikuta J (1831) Sphingosine-1-phosphate signaling controlling osteoclasts and bone homeostasis. Biochim Biophys Acta 2013:223–227
21.
go back to reference Dziak R (2013) The role of sphingosine-1-phosphate (S1P) and lysophosphatidic acid (LPA) in regulation of osteoclastic and osteoblastic cells. Immunol Invest 42:510–518CrossRefPubMed Dziak R (2013) The role of sphingosine-1-phosphate (S1P) and lysophosphatidic acid (LPA) in regulation of osteoclastic and osteoblastic cells. Immunol Invest 42:510–518CrossRefPubMed
22.
go back to reference Kim BJ, Shin KO, Kim H, Ahn SH, Lee SH, Seo CH, Byun SE, Chang JS, Koh JM, Lee YM (2016) The effect of sphingosine-1-phosphate on bone metabolism in humans depends on its plasma/bone marrow gradient. J Endocrinol Invest 39:297–303CrossRefPubMed Kim BJ, Shin KO, Kim H, Ahn SH, Lee SH, Seo CH, Byun SE, Chang JS, Koh JM, Lee YM (2016) The effect of sphingosine-1-phosphate on bone metabolism in humans depends on its plasma/bone marrow gradient. J Endocrinol Invest 39:297–303CrossRefPubMed
23.
24.
go back to reference Roth AG, Drescher D, Yang Y, Redmer S, Uhlig S, Arenz C (2009) Potent and selective inhibition of acid sphingomyelinase by bisphosphonates. Angew Chem Int Ed Engl 48:7560–7563CrossRefPubMed Roth AG, Drescher D, Yang Y, Redmer S, Uhlig S, Arenz C (2009) Potent and selective inhibition of acid sphingomyelinase by bisphosphonates. Angew Chem Int Ed Engl 48:7560–7563CrossRefPubMed
25.
go back to reference von Ranke FM, Pereira Freitas HM, Mancano AD, Rodrigues RS, Hochhegger B, Escuissato D, Araujo Neto CA, da Silva TK, Marchiori E (2016) Pulmonary involvement in Niemann–Pick disease: a state-of-the-art review. Lung 194:511–518CrossRef von Ranke FM, Pereira Freitas HM, Mancano AD, Rodrigues RS, Hochhegger B, Escuissato D, Araujo Neto CA, da Silva TK, Marchiori E (2016) Pulmonary involvement in Niemann–Pick disease: a state-of-the-art review. Lung 194:511–518CrossRef
Metadata
Title
Hepatosplenomegaly, pneumopathy, bone changes and fronto-temporal dementia: Niemann–Pick type B and SQSTM1-associated Paget’s disease in the same individual
Authors
Camelia Voinea
Elena Gonzalez Rodriguez
Catherine Beigelman-Aubry
Victor Leroy
Bérengère Aubry-Rozier
Belinda Campos-Xavier
Diana Ballhausen
Romain Lazor
Frédéric Barbey
Luisa Bonafé
Andrea Superti-Furga
Christel Tran
Publication date
01-03-2019
Publisher
Springer Japan
Published in
Journal of Bone and Mineral Metabolism / Issue 2/2019
Print ISSN: 0914-8779
Electronic ISSN: 1435-5604
DOI
https://doi.org/10.1007/s00774-018-0932-1

Other articles of this Issue 2/2019

Journal of Bone and Mineral Metabolism 2/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine